Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.
This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.
Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension | At the time of the first visit |
| Measure | Description | Time Frame |
|---|---|---|
| Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population. | At the time of the first visit | |
| Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subject selection would be from clinics in a primary care setting
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Algiers | 16015 | Algeria | |||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30876390 | Derived | Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2. | |
| 29530274 |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole Blood
| At the time of the first visit |
| Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups. | At the time of the first visit |
| Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic. | At the time of the first visit |
| Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic. | At the time of the first visit |
| Bejaja |
| 6000 |
| Algeria |
| Pfizer Investigational Site | Djelfa | 17000 | Algeria |
| Pfizer Investigational Site | Laghouat | Algeria |
| Pfizer Investigational Site | M'Sila | Algeria |
| Pfizer Investigational Site | Relizane | 48000 | Algeria |
| Pfizer Investigational Site | Saida | 20000 | Algeria |
| Pfizer Investigational Site | Tébessa | Algeria |
| Pfizer Investigational Site | Tlemcen | 13000 | Algeria |
| Pfizer Investigational Site | Yaoundé | Cite Verte | Cameroon |
| Pfizer Investigational Site | Douala | Deido | Cameroon |
| Pfizer Investigational Site | Bafoussam | Cameroon |
| Pfizer Investigational Site | Mbandjok | Cameroon |
| Pfizer Investigational Site | Njombé | Cameroon |
| Pfizer Investigational Site | Okoa | Cameroon |
| Pfizer Investigational Site | Alexandria | Egypt |
| Pfizer Investigational Site | Cairo | Egypt |
| Pfizer Investigational Site | Shiben Al Kom | Egypt |
| Pfizer Investigational Site | Tanta | Egypt |
| Pfizer Investigational Site | Accra | Ghana |
| Pfizer Investigational Site | Jachie-Ashanti | Ghana |
| Pfizer Investigational Site | Kumasi | Ghana |
| Pfizer Investigational Site | Sogakope V/R | Ghana |
| Pfizer Investigational Site | Takoradze | Ghana |
| Pfizer Investigational Site | Amman | Jordan |
| Pfizer Investigational Site | Irbid | Jordan |
| Pfizer Investigational Site | Salt | Jordan |
| Pfizer Investigational Site | Chongoria | 60401 | Kenya |
| Pfizer Investigational Site | Nairobi | 00508 | Kenya |
| Pfizer Investigational Site | Adailiya | Kuwait |
| Pfizer Investigational Site | Al Faḩāḩīl | Kuwait |
| Pfizer Investigational Site | Kuwait City | Kuwait |
| Pfizer Investigational Site | Mishrif | Kuwait |
| Pfizer Investigational Site | Qadesya | Kuwait |
| Pfizer Investigational Site | Yarmouk | Kuwait |
| Pfizer Investigational Site | Jbeil, Lebanon | Lebanon | Lebanon |
| Pfizer Investigational Site | Beirut | Lebanon |
| Pfizer Investigational Site | Jounieh | Lebanon |
| Pfizer Investigational Site | Tripoli | Lebanon |
| Pfizer Investigational Site | Abuja, FCT | Nigeria |
| Pfizer Investigational Site | Abuja, Garki | Nigeria |
| Pfizer Investigational Site | Calabar | Nigeria |
| Pfizer Investigational Site | Enugu | Nigeria |
| Pfizer Investigational Site | Keffi, Nassarawa | Nigeria |
| Pfizer Investigational Site | Dammam | Saudi Arabia |
| Pfizer Investigational Site | Jeddah | Saudi Arabia |
| Pfizer Investigational Site | Mecca | Saudi Arabia |
| Pfizer Investigational Site | Riyadh | 11584 | Saudi Arabia |
| Pfizer Investigational Site | Riyadh | Saudi Arabia |
| Pfizer Investigational Site | Yanbu | Saudi Arabia |
| Pfizer Investigational Site | Dakar | Nabil Choucair | Senegal |
| Pfizer Investigational Site | Dakar | Ouakam | Senegal |
| Pfizer Investigational Site | Kedoungou | Senegal |
| Pfizer Investigational Site | Kébémer | Senegal |
| Pfizer Investigational Site | Saint-Louis | Senegal |
| Pfizer Investigational Site | Ziguinchor | Senegal |
| Pfizer Investigational Site | Halfway House | Gauteng | 1685 | South Africa |
| Pfizer Investigational Site | Sydenham, Durban | KwaZulu-Natal | 4091 | South Africa |
| Pfizer Investigational Site | Mokopane | Limpopo | 0600 | South Africa |
| Pfizer Investigational Site | Sheshego | Limpopo | 0742 | South Africa |
| Pfizer Investigational Site | Mamelodi East | Pretoria | 0122 | South Africa |
| Pfizer Investigational Site | Kwa-Zulu Natal | 4091 | South Africa |
| Pfizer Investigational Site | Rondebosch | 7700 | South Africa |
| Pfizer Investigational Site | Aryanah | 2073 | Tunisia |
| Pfizer Investigational Site | Bouficha | 4010 | Tunisia |
| Pfizer Investigational Site | Messaadine | 4013 | Tunisia |
| Pfizer Investigational Site | Sfax | 3013 | Tunisia |
| Pfizer Investigational Site | Tunis | 1000 | Tunisia |
| Pfizer Investigational Site | Zaghouan | 1100 | Tunisia |
| Pfizer Investigational Site | Abu Dhabi | United Arab Emirates |
| Pfizer Investigational Site | Al Ain City | United Arab Emirates |
| Pfizer Investigational Site | Dubai | United Arab Emirates |
| Pfizer Investigational Site | Ras Al Khaima | United Arab Emirates |
| Derived |
| Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French. |
| 29449941 | Derived | Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018. |
| 28983166 | Derived | Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14. |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D012907 | Smoking |
| D050171 | Dyslipidemias |
| D003920 | Diabetes Mellitus |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D044882 | Glucose Metabolism Disorders |
| D004700 | Endocrine System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided